The Study of Terazosin in the Treatment of Chronic Prostatitis III_B

YIN Hang,WANG Xiaofeng,BAI Wenjun,BAI Yan,LIU Haokun
DOI: https://doi.org/10.3969/j.issn.1001-1420.2005.03.012
2005-01-01
Journal of Clinical Urology
Abstract:Objective:To investigate the mechanism of chronic prostatitis (CP) and define the best guidance for its clinical treatment by studying the efficacy of Terazosin and also detecting the expression of Prostaglandin E_2(PGE_2) in expressed prostatic secretion (EPS).Methods:Standardized clinical surveys were completed in 46 patients who met the criteria for CP by physical examination, urine and EPS analysis and urine culture, including 46 cases of CP Ⅲ_B which were treated with alpha 1-adrenoceptor antagonist(Terazosin)for 4 weeks. Symptom scores (NIH-CPSI) and urodynamic indexes were recorded and the expression of PGE_2 in EPS of CP patients and normal asymptomatic controls were detected by enzyme-linked immumosorbent assay pre- and post-treatment.Results:Mean levels of PGE_2 in EPS were significantly higher in treated arms than in normal controls before treatment (P 0.05). Mean levels of PGE_2 in EPS of post-treatment group were significantly lower than those of pre-treatment counterparts (P 0.05). NIH-CPSI after treatment were significantly lower than that before treatment (P 0.05), Urodynamic indexes of post-treatment were significantly lower than those of pre-treatment counterparts (P 0.05).Conclusions:The results of the present study indicate that the levels of PGE_2 in EPS may play an important role in CP and are associated with symptoms of CP. Alpha 1-adrenoceptor antagonist (Terazosin) significantly reduced the levels of inflammation factors such as PGE_2 and may improve the efficacy in the treatment of CP.
What problem does this paper attempt to address?